Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.


NDAQ:INM - Post by User

Comment by Steveminon Jun 29, 2021 4:35pm
100 Views
Post# 33467790

RE:News - Private Placement $12M

RE:News - Private Placement $12MI actually laughed when i saw the news of this private placement. In typical Adams' fashion, he puts out what ordinarily would be good news (acquiring Baymedica), then kicks you in the nuts with a massively dilutive cap raise.
Remember the "hey we're moving to the Nasdaq" following by "but we are gonna do a 1:33 reverse split".... ugh, this guy is truly disgusting.

The cap raise alone (warrants included) just doubled the share count. 100% DILUTION - not even incuding the Baymedica deal!!!
Please, please somebody show me another company that dilutes 100% at a time (on the Nasdaq).

Remember they just diluted 4 months ago in February as well as 3 months prior to that in November.

Man o man, he is absolutely fleecing his shareholders. 
The sp got a nice bump today but there's no way it will sustain. Common sense (and valuation alone) will prove that. I have said it before and will say it again - at this sp and the rate of dilution, there's seemingly little chance they can maintain the qualifications to stay on the Nasdaq......
<< Previous
Bullboard Posts
Next >>